VolitionRx (VNRX) announced the results of a large-scale study which shows that its Nu.Q Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT or LDCT scan, ...
HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of ...
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results